hi Geezer, would like to clarify with regards to the Merck deal....

hi Geezer,

would like to clarify with regards to the Merck deal. pls read the following excerpt from the Merck licensing agreement ann earlier.

Under the terms Anteo will be required to manufacture and deliver the New Products to Merck. Launch of the New Products is expected in July/August 2010. Merck will be responsible for the sales and distribution of the New Products which will be launched in the Bio-Estapor product line. Initial sales within the first 6 months are expected to be minimal as Merck focuses on assessing the market for the New Products within their existing customer base and distribution network.
Similarly to the Licensing Agreement entered into with Bangs, these minimal initial revenue streams are consistent with a typical sales cycle associated with selling new technologies such as Mix&GoTM into these markets.
The agreed terms do not require Merck to provide forecast product requirements until 2012 after which 12 month rolling forecasts are to be provided.


ADO should already be recieving royalties from these products.

one of the directors mentioned before that ADO aims to be cash flow positive by middle of 2011. the biotech sector like alot of the others are slow at the start but growth is like an exponential curve. just think about it as e snowball effect.

i hope u do more research and more confident in ADO and invest accordingly. best wishes to all sh